Últimas noticias sobre Pliant Therapeutics (NASDAQ:PLRX) Bolsa

PLIANT THERAPEUTICS INC

Pliant Therapeutics

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.

Pliant Therapeutics Inc

RNAZ

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Nexxen International Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) reported better-than-expected earnings for its <a href="https://www.benzinga.com/quote/NEXN/earnings">first quarter on Wednesday</a>.
The company posted quarterly earnings of 16 cents per share which beat the analyst consensus estimate of 5 cents per share. The company reported quarterly sales of $78.33 million which beat the analyst consensus estimate of $76.60 million.
&#8220;Our momentum continued in Q1 fueling record results driven by CTV, alongside significant Adjusted EBITDA growth,&#8221; said Ofer Druker, Chief Executive Officer of Nexxen. &#8220;We believe these results reflect the payoff from years of investment in our technology, data capabilities and brand. Industry partners are increasingly embracing our full stack of interconnected AI-powered data and technology solutions &#8211; driving greater spending, deeper adoption and long-term growth potential, even in uncertain market conditions.&#8221;
Nexxen shares fell 5.7% to close at $11.62 on Wednesday.
These analysts made changes to their price targets on Biodesix following earnings announcement.
<ul class="wp-block-list">
<li>Needham analyst Laura Martin maintained Nexxen International with a Buy and raised the price target from $12 to $14.</li>
<li>Rosenblatt analyst Barton Crockett maintained the stock with a Buy and raised the price target from $15 to $16.</li>
<li>JMP Securities analyst Matthew Condon maintained the stock with a Market Outperform and raised the price target from $11 to $15.</li>
</ul>
Considering buying CL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image is-resized"><img decoding="async" src="blob:https://editorial.benzinga.com/4011d15f-e260-4f74-87ae-27141197fbc9" alt="" style="width:664px;height:auto" /></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/25/05/45405004/jim-cramer-sofi-goes-to-new-highs-recommends-not-buying-this-health-care-stock">Jim Cramer: SoFi Goes To &#8216;New Highs,&#8217; Recommends Not Buying This Health Care Stock</a> </li>
</ul>
Photo via Shutterstock

Earnings

News

Price Target

Markets

Analyst Ratings

Trading Ideas

NEXN

Nexxen International Analysts Boost Their Forecasts After Upbeat Q1 Results

Barclays analyst Raimo Lenschow maintains Dynatrace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) with a Overweight and raises the price target from $55 to $62.

Barclays Maintains Overweight on Dynatrace, Raises Price Target to $62

WIIM

POAI

Predictive Oncology shares are trading higher after the company reported a year-over-year increase in Q1 financial results.

APRE

Aprea Therapeutics shares are trading higher on continued strength after the company reported a year-over-year increase in Q1 EPS results on Wednesday..

Barclays analyst Raimo Lenschow maintains CoreWeave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) with a Overweight and raises the price target from $60 to $70.

CRWV

Barclays Maintains Overweight on CoreWeave, Raises Price Target to $70

Biotech

General

SELLAS Life Sciences Doses First Pediatric AML Patient In Ongoing Phase 2 Trial Of SLS009 r/r AML

CETX

Cemtrex Q2 EPS $4.10, Sales $27.25M Up From $17.16M YoY

LAZR

Luminar Technologies shares are trading lower after JP Morgan downgraded the stock from Overweight to Neutral.

Foot Locker, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) shares rocketed premarket on Thursday after the company disclosed a definitive deal to be acquired by Dick&#8217;s Sporting Goods Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>), which values Foot Locker&#8217;s equity at around $2.4 billion and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45431136/dicks-sporting-goods-to-acquire-foot-locker-to-create-a-global-leader-in-the-sports-retail-industr" rel="noreferrer noopener">its enterprise at about $2.5 billion</a>.
DICK&#8217;S plans to fund the acquisition using a combination of its existing cash reserves and newly incurred debt.
As per the deal, Foot Locker shareholders will have the option to receive either $24.00 in cash or 0.1168 shares of DICK&#8217;S common stock for each share of Foot Locker common stock they own.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/sports/25/05/45424475/foot-locker-stock-soars-on-potential-dicks-sporting-goods-deal-report" rel="noreferrer noopener">Foot Locker Stock Soars On Potential Dick&#8217;s Sporting Goods Deal: Report</a>
Based on Foot Locker&#8217;s closing stock price on May 14, 2025, the $24.00 per-share consideration reflects a premium of about 66% over Foot Locker&#8217;s 60-trading-day volume-weighted average price.
The transaction is expected to close in the second half of 2025, upon shareholder approval and other customary closing conditions.
Synergy &amp; Benefits: DICK&#8217;S anticipates that this acquisition to increase its EPS starting in the first full fiscal year after the deal closes, excluding transaction and other one-time costs related to achieving synergies.
The company also expects to realize between $100 million and $125 million in cost synergies in the medium term through efficiencies in <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">procurement and direct sourcing</a>.
Ed Stack, Executive Chairman of DICK&#8217;S said, &#8220;By applying our operational expertise to this iconic business, we see a clear path to further unlocking growth and enhancing Foot Locker&#8217;s position in the industry. Together, we will leverage the complementary strengths of both organizations to better serve the broad and evolving needs of global sports retail consumers.&#8221;
Mary Dillon, CEO of Foot Locker added, &#8220;By joining forces with DICK&#8217;S, Foot Locker will be even better positioned to expand sneaker culture, elevate the omnichannel experience for our customers and brand partners, and enhance our position in the industry.&#8221;
DKS Q1 Preliminary: The company sees comparable sales growth of 4.5% and adjusted EPS of&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45431210/dicks-sporting-goods-reports-preliminary-results-for-first-quarter-of-2025-reports-comparable-sale" rel="noreferrer noopener">$3.37 vs. the consensus of&nbsp;$3.22</a>. The company will report first-quarter <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">results&nbsp;on&nbsp;May 28, 2025</a>.
FL Q1 Preliminary: The company expects a comparable sales decline of 2.6% year over year (Y/Y), with comparable sales in the&nbsp;North <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45431211/foot-locker-inc-reports-preliminary-first-quarter-2025-financial-results" rel="noreferrer noopener">America&nbsp;region decreasing by 0.5%</a>.
Foot Locker projects adjusted loss per share of&nbsp;7 cents&nbsp;in the first quarter (consensus of $0.41), vs. EPS of&nbsp;22&nbsp;cents in the corresponding prior-year period.
Adjusted loss per share excludes non-cash impairment charges totaling&nbsp;$276 million&nbsp;and reflects a&nbsp;$140 million&nbsp;charge related to a&nbsp;tradename and a goodwill impairment charge of&nbsp;$110 million.
Also, the company recorded a full valuation allowance on deferred tax assets and deferred tax costs related to the European business totaling&nbsp;$124 million.
Foot Locker will report results on May 29, 2025.
As of February&nbsp;1, 2025, DICK&#8217;S cash and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44242779/dicks-sporting-goods-reports-fourth-quarter-and-full-year-2024-results-delivers-largest-sales-quar" rel="noreferrer noopener">cash equivalents stood at $1.69 billion</a>.
Price Action: FL shares are up 83.30% at $23.59, while DKS stock dipped 11.70% at $185.10&nbsp;premarket at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/25/04/44672618/trump-tariffs-to-hurt-nike-under-armour-vf-are-ralph-lauren-foot-locker-safer-bets" target="_blank" rel="noreferrer noopener">Trump Tariffs To Hurt Nike, Under Armour, VF: Are Ralph Lauren, Foot Locker Safer Bets?</a></li>
</ul>
Photo by C. Nass via Shutterstock

Large Cap

Guidance

Movers

Dick's Sporting Goods To Acquire Foot Locker At 66% Premium

Bitcoin Depot shares are trading higher after the company reported a year-over-year increase in Q1 EPS results and better-than-expected sales results.

Barclays analyst Tim Long maintains Cisco Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) with a Equal-Weight and raises the price target from $61 to $66.

CSCO

Barclays Maintains Equal-Weight on Cisco Systems, Raises Price Target to $66

April retail sales data showed that the <a href="https://www.benzinga.com/topic/tariffs">round of tariffs</a> announced by President Donald Trump on &#8220;Liberation Day&#8221; started to produce their effects by reducing household consumption.
However, while households reined in spending, inflationary pressures at the producer level unexpectedly contracted in April, notching the biggest decline since April 2020 and highlighting the disinflationary impact of tariffs on input costs across industries.
U.S. retail sales grew only by 0.1% in April from the previous month, a report from the Census Bureau showed Thursday. The outcome marks a sharp reversal from March's upwardly revised 1.7% gain, yet slightly topped economist expectations of no change.
A relevant drag came from motor vehicles and parts which contracted by 0.1%. In March, auto-related sales jumped 5.5% as consumers rushed to buy before tariffs took effect. 
Stripping out autos, retail sales also rose 0.1%, a slowdown from March's 0.8% increase and below the 0.3% consensus. 
When excluding both gasoline and autos, the figure improves slightly to a 0.2% rise, though it still marks a deceleration from March's 1.1% growth.
On an annual basis, April retail sales were up 5.2% from a year earlier, unchanged from March.
<h3 class="wp-block-heading">Tariffs Slash Producer Prices</h3>
The Producer Price Index fell 0.5% month over month, marking the sharpest decline since April 2020. This was a steep reversal from March's flat reading and missed economists&#8217; expectations for a 0.2% increase.
On a year-over-year basis, producer inflation cooled to 2.4%, down from 3.1% in March and undercutting forecasts of 2.5%.
&#8220;The April decline in the index for final demand is attributable to prices for final demand services, which decreased 0.7%,&#8221; the Bureau of Labor Statistics said.
More than 40% of April's drop in the final demand services index stemmed from a 6.1% decline in margins for machinery and vehicle wholesaling. Additional declines were recorded in portfolio management, food and alcohol wholesaling, system software publishing, traveler accommodations, and airline passenger services.
Core producer prices, which exclude food and energy, dropped 0.4% on the month, wiping out the previous month's 0.4% gain and coming in well below the 0.3% estimate. 
On an annual basis, core PPI rose 3.1%, easing from 4% in March but in line with consensus.
<h3 class="wp-block-heading">Market Reaction: Yields Rise, Stocks Slip</h3>
U.S. stock futures pulled back after a three-day rally. By 8:40 a.m. ET, futures on the S&amp;P 500 were down 0.3%, while Nasdaq 100 futures fell 0.4%.
Meanwhile, the U.S. Dollar Index (DXY) – as tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) – fell to 100.7 levels. 
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45430835/us-stocks-likely-to-open-lower-after-sp-500s-three-day-winning-streak-many-uncertainties-remain-says-expert">US Stocks Likely To Open Lower After S&amp;P 500&#8217;s Three-Day Winning Streak: &#8216;&#8230;Many Uncertainties Remain,&#8217; Says Expert </a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Macro Economic Events

Econ #s

Economics

PowerShares DB US Dollar Index Bullish Fund

Tariffs Slow Retail Spending As Producer Prices Post Sharpest Drop Since 2020

Watching Walmart; During Conf Call, CFO Reportedly Says February Was Softer Than Expected, March Was Back To Norma And April Was Very Strong; We Will Need To Manage Quantity Volumes As We Measure Tariffs

ATER

Aterian shares are trading lower following Q1 reported financial results.

BNGO

Bionano Genomics shares are trading higher after the company reported better-than-expected Q1 financial results.

GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) reported quarterly losses of $(5.80) per share which missed the analyst consensus estimate of $(4.11) by 41.12 percent. This is a 94.26 percent increase over losses of $(101.05) per share from the same period last year.

Earnings Misses

ALPS ETF Trusthen & Steers Global Realty Majors ETF

GRI Bio Q1 EPS $(5.80) Misses $(4.11) Estimate

New solution unites America's only nationwide 5G Advanced network with industry-leading Prisma SASE 5G to offer more secure, comprehensive connectivity for businesses and government agencies
Today, T-Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) and Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) introduced ‘T-Mobile SASE, with Palo Alto Networks' — a new managed offering that brings together <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.t-mobile.com%2Fnews%2Fnetwork%2Ft-mobile-reaches-5g-advanced-nationwide-milestone-unlocks-the-modern-wireless-network-for-consumers-businesses-and-developers&amp;esheet=54255536&amp;newsitemid=20250515144479&amp;lan=en-US&amp;anchor=America%26%238217%3Bs+only+nationwide+5G+Advanced+network&amp;index=1&amp;md5=9446c88e82de55d98bfa5aff4ac88267">America's only nationwide 5G Advanced network</a>, T-Mobile's T-SIMsecure with T-Mobile Security Slice and Palo Alto Networks' industry-leading <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.paloaltonetworks.com%2Fsase%2F5G-for-service-providers&amp;esheet=54255536&amp;newsitemid=20250515144479&amp;lan=en-US&amp;anchor=Prisma+SASE+5G&amp;index=2&amp;md5=f73fbde5bc7f1cdee82d4dc408cba17c">Prisma SASE 5G</a>. The offering will deliver enhanced protection, performance and simplicity to T-Mobile for Business customers.
Palo Alto Networks Prisma SASE 5G, the cloud-native Zero Trust security solution, expands T-Mobile's security portfolio enabling organizations to better protect their networks and devices without the need for extra equipment or additional software. It empowers businesses and government agencies to more securely connect users and devices to private, Software as a Service (SaaS) and internet applications while maintaining strict security policies and visibility. By integrating Palo Alto Networks' SASE capabilities into T-Mobile's network, customer data has increased protection across endpoints.

PANW

TMUS

T-Mobile And Palo Alto Networks Introduce Managed SASE Offering For Wireless Devices

Barclays analyst Michael Leithead maintains Axalta Coating Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXTA#NYSE">AXTA</a>) with a Overweight and lowers the price target from $45 to $42.

AXTA

Barclays Maintains Overweight on Axalta Coating Systems, Lowers Price Target to $42

NWTG

Newton Golf Company shares are trading higher after the company reported a year-over-year increase in Q1 financial results.

Health Care

Press Releases

Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

Legal

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics – PLRX

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics

Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. – PLRX

Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Comments

Pliant Therapeutics

Noticias

Últimas noticias sobre Pliant Therapeutics (NASDAQ:PLRX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL